Related Experiment Video
Updated: Apr 21, 2026
06:33
Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
Published on: February 2, 2024
2.7K
Ideal basal insulin: opportunities from designer proteins
The Journal of the Association of Physicians of India
|October 22, 2014
Summary
Insulin degludec offers an ideal basal insulin therapy for diabetes, providing predictable glucose control and a lower risk of hypoglycemia with a once-daily dose. This advancement enhances adherence and improves glycemic management for patients with type 1 and type 2 diabetes.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Achieving near-normal glycemic profiles in insulin therapy is crucial.
- Minimizing weight gain and hypoglycemia are key challenges in diabetes management.
- Flexible insulin regimens improve patient adherence and glycemic control.
Purpose of the Study:
- To evaluate insulin degludec as an ideal basal insulin.
- To assess its impact on glycemic control and patient adherence.
- To highlight its benefits in managing type 1 and type 2 diabetes.
Main Methods:
- Pharmacodynamic and pharmacokinetic profiling of insulin degludec.
- Assessment of glycemic excursions and variability.
- Evaluation of hypoglycemia risk and weight gain.
Main Results:
- Insulin degludec demonstrates a long duration of action and a flat pharmacodynamic profile.
- Low day-to-day variability leads to predictable glucose levels.
- Effective glycemic control with reduced risk of hypoglycemia is achieved with once-daily administration.
Conclusions:
- Insulin degludec meets the criteria for an ideal basal insulin.
- It offers predictable glycemic control and a low hypoglycemia risk.
- Represents a significant advancement in the treatment of type 1 and type 2 diabetes.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
2.0K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.0K
01:30Production of Pharmaceuticals
88
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
88
01:27Insulin Formulations: Types and Delivery
1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.1K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
997
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
997